Intercept loses Ocaliva FDA full approval bid in rare liver disease
The FDA declined to approve Intercept Pharmaceutical's Ocaliva for primary biliary cholangitis following an unfavorable AdCom meeting. The drug will continue to be available under accelerated approval, with further discussions planned with the FDA.